Back to Newsroom

Novavax to offer $200M in convertible debt; shares down 7% premarket

  • Novavax Announces Proposed Offering of $200 Million of Convertible Senior Notes Due 2023 –

    GAITHERSBURG, Md., Jan. 25, 2016 (GLOBE NEWSWIRE) — Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that it intends to offer, subject to market and other conditions, $200 million aggregate principal amount of convertible senior unsecured notes that will mature on February 1, 2023.